Evidence of novel oral anticoagulants (NOAC)

研究成果: ジャーナルへの寄稿学術誌査読

2 被引用数 (Scopus)

抄録

Novel oral anticoagulants (NOAC) such as the direct thrombin inhibitor, dabigatran, and oral factor Xa inhibitors, rivaroxaban and apixaban, have recently approved for prevention of stroke in nonvalvular atrial fibrillation (NVAF). Phase III trials have compared each of these agents to warfarin. Dabigatran was more efficacious than warfarin in reducing the risk of stroke when given at a dose of 150?mg BID to patients with NVAF. Rivaroxaban 20?mg QD was superior to warfarin in on-treatment analysis. Apixaban 5?mg BID was also found to be superior to warfarin in reducing stroke in NVAF patients. Of note, the rate of hemorrhagic stroke was much smaller in the patients treated with NOAC than those with warfarin. NOAC offer a good therapeutic option for prevention of stroke in NVAF patients.

本文言語英語
ページ(範囲)992-993
ページ数2
ジャーナルClinical Neurology
53
11
DOI
出版ステータス出版済み - 2013

!!!All Science Journal Classification (ASJC) codes

  • 臨床神経学

フィンガープリント

「Evidence of novel oral anticoagulants (NOAC)」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル